Making trade-offs explicit: development and pilot of a Belgian MCDA framework for orphan drug appraisal
International Journal of Technology Assessment in Health Care · 2026
DOI: 10.1017/s0266462326104127 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Technology Assessment in Health Care, 2026. Verfasst von Alessandra Blonda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium. Hauptthemen laut MEDLINE: Orphan Drug Production, Technology Assessment, Biomedical, Decision Support Techniques. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Objectives
Orphan drug reimbursement remains a contested area in health technology assessment (HTA), as decision makers must balance limited evidence, high unmet need, patient-relevant value, and affordability. Multi-criteria decision analysis (MCDA) has been proposed to make such trade-offs more explicit and transparent, yet empirical applications in European national HTA settings remain scarce.
Methods
We developed and piloted an MCDA framework for orphan drug reimbursement in Belgium. Candidate criteria were identified through a systematic literature review. A multidisciplinary expert panel (comprising representatives from the national reimbursement agency, sickness funds, patient organizations, pharmaceutical companies, clinicians, and bioethicists) participated in four focus group discussions to select and define criteria. Criterion weights were elicited through a three-round Delphi process. The framework was piloted on four orphan drugs previously appraised in Belgium: ponatinib, pirfenidone, onasemnogene abeparvovec, and metreleptin.
Results
Seven quantitative and three qualitative contextual criteria were selected. Unmet medical need received the highest weight, followed by comparative effectiveness and impact on patient-reported outcomes. Onasemnogene abeparvovec achieved the highest overall MCDA score (0.77), followed by metreleptin (0.65), pirfenidone (0.47), and ponatinib (0.39). The pilot also generated policy-relevant insights on criterion design, handling residual uncertainty, separating value assessment from reimbursement feasibility (through cost criteria), and using scores to support–rather than replace–deliberation.
Conclusion
This study presents the first MCDA framework for orphan drug reimbursement in Belgium and illustrates how criterion weights and scores can structure committee deliberation, complemented by contextual appraisal, to support more transparent, consistent, and accountable decision making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.
- Tufts University, USA.
- Public Health and Primary Care, KU Leuven, Belgium.
ORCID-Profile: Alessandra Blonda
Förderung
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Blonda, A., Ollendorf, D. A., Huys, I., Denier, Y., & Simoens, S. (2026). Making trade-offs explicit: development and pilot of a Belgian MCDA framework for orphan drug appraisal. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462326104127
Vancouver
Blonda A, Ollendorf DA, Huys I, Denier Y, Simoens S. Making trade-offs explicit: development and pilot of a Belgian MCDA framework for orphan drug appraisal. International Journal of Technology Assessment in Health Care. 2026. doi:10.1017/s0266462326104127
BibTeX
@article{Blonda2026,
author = {Blonda, Alessandra and Ollendorf, Daniel A and Huys, Isabelle and Denier, Yvonne and Simoens, Steven},
title = {Making trade-offs explicit: development and pilot of a Belgian MCDA framework for orphan drug appraisal},
journal = {International Journal of Technology Assessment in Health Care},
year = {2026},
doi = {10.1017/s0266462326104127}
}
EUVIMED